Shingles Vaccine (inactivated, genetically engineered, with Adjuvant System)
Contains ASO1B as an Adjuvant System to enhance and prolong immune response, resulting in high and long-lasting effectiveness.
Recommended for individuals aged 50 and older, and for those aged 18 and older with immunocompromised conditions.
Administered as 2 doses (0.5 ml per dose), spaced 2–6 months apart. No booster is required after completing both doses.
Studied across 18 countries with 30,000 participants.
A follow-up study over more than 10 years shows a protection efficacy of 89% against shingles.
Can be administered to those who have previously received the live attenuated shingles vaccine.
Can be given alongside flu vaccine, pneumococcal polysaccharide vaccine (23-valent), and pneumococcal conjugate vaccine without affecting immune response.
For those who have previously received the live attenuated shingles vaccine, the new vaccine can be administered after 6 months, requiring a full 2-dose series.
Prevents complications from shingles, such as vasculitis, disease spread, ocular disease, neurological issues, stroke, and internal organ-related diseases.
Protection rates:
97.2% effective in preventing shingles
93% effective in preventing postherpetic neuralgia (PHN)
93.7% effective in reducing shingles complications
84.7% reduction in hospitalization rates
39.6% reduction in pain medication use and duration for shingles-related pain
Notes:
This price includes all doctor fees and service charges.
Please schedule an appointment in advance for vaccination.
This price is applicable for cash or credit card payments only.
Payment is non-refundable.
This price cannot be combined with other promotions or discounts.
English
ภาษาไทย
